If the partner for ELI-216 Phase III trial is Watson/Actavis. Watson foots the cost for the ELI-216 Phase III and in return Watson and Elite structure a contract for Elite to apply it to Watson Morphine Sulphate opioid product that is in competition with Pfizer/King Embeda.
Elite's new 15,000 sq ft manufacturing space is idle.
Elite keeps 100% of the profits for ELI-216 oxycodone/naltrexone and in turn JVs with Watson to manufacture Watson's Morphine opioid at Elite's NJ 30,000 sq ft facilities.
Expected cost for Elite's FDA 300 person ELI-216 Phase III trial is $7 mil. Watson funds it and Watson gets $7 mil back many times over with the profits from the successful marketing of its new Morphine agonist/antagonist ELI-216 2-bead product manufactured by Elite for Watson.
Lasers, I have lost track but will that be the MM Short Squeeze IV this year? If there is an Watson/Activis or other pharma funding, it is my opinion that the MMs would know about it before the rest of the investors find out.
Market Data 
Markets 
AI
